Everett Harris & Co. CA Has $78.69 Million Position in Becton, Dickinson and Company (BDX)

Everett Harris & Co. CA lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 0.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,302 shares of the medical instruments supplier’s stock after buying an additional 2,365 shares during the quarter. Becton, Dickinson and comprises approximately 2.4% of Everett Harris & Co. CA’s holdings, making the stock its 13th biggest position. Everett Harris & Co. CA owned approximately 0.19% of Becton, Dickinson and worth $78,688,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BDX. North Star Investment Management Corp. lifted its holdings in Becton, Dickinson and by 3.4% during the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the last quarter. Almanack Investment Partners LLC. acquired a new stake in Becton, Dickinson and during the 1st quarter valued at $105,000. Parkside Financial Bank & Trust lifted its holdings in Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY lifted its holdings in Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares during the last quarter. Finally, Financial Architects Inc lifted its holdings in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. 87.43% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 195.34 on Friday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock’s 50 day moving average price is $199.43 and its 200-day moving average price is $191.33. The firm has a market cap of $44.45 billion, a P/E ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.35 EPS. On average, analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.49%. Becton, Dickinson and’s payout ratio is 83.43%.

ILLEGAL ACTIVITY NOTICE: “Everett Harris & Co. CA Has $78.69 Million Position in Becton, Dickinson and Company (BDX)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/09/17/everett-harris-co-ca-has-78-69-million-position-in-becton-dickinson-and-company-bdx.html.

In other news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock valued at $15,242,688 in the last quarter. 1.40% of the stock is owned by corporate insiders.

BDX has been the subject of several research reports. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and presently has an average rating of “Buy” and a consensus target price of $196.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply